Overview

Pilot Study on Immunotherapy for the Treatment of Persistant Peanut Allergy

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the safety and efficacy of peanut immunotherapy in children and adults with peanut allergy. Participants will receive immunotherapy with peanut every 2 weeks for a period of 3 months.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University Hospital, Geneva